Aptar Pharma will unveil Prohaler®, the smart DPI for optimal patient compliance
During the next edition of CPHI/ICSE Europe tradeshow which be held on October 7th to October 9th, in Paris Villepinte, Aptar Pharma will introduce Prohaler?, the smart DPI for optimal patient.
Aptar Pharma will unveil Prohaler®, the smart DPI for optimal patient compliance
During the next edition of CPHI/ICSE Europe tradeshow which be held on October 7th to October 9th, in Paris Villepinte, Aptar Pharma will introduce Prohaler®, the smart DPI for optimal patient.
The Prohaler® DPI has been developed with a patient-based design approach which makes it intuitive and simple to use by all asthma and COPD patients.
Prohaler® features a novel powder dispersion technology enabling consistent lung deposition even while operating at relatively low patient inhalation flow rates. The results of a recent research showed that Prohaler® has excellent ergonomics, providing intuitive and constant handling characteristics. It is easy to use, with only 3 simple steps needed: open the device, inhale and close it; inhaling triggers the release of a full dose of medication. And a dose counter reminds the patient how many doses are left in the device.
Prohaler® incorporates visual and audible feed-back systems to facilitate ease-of-use and patient compliance.
Prohaler® also has a unique patient safety feature to avoid any risk of double-dosing and wasted doses. And the drug product is protected inside individual blisters which are only opened upon inhalation by the patient, providing optimal powder protection.
For more information on Prohaler®, please visit our booth #2F35, hall 2, or our website: www.aptar.com/pharma
Contact details:
Aptar Pharma
36-36 Rue de la Princesse
78431 Louveciennes Cedex - France
Telephone number: + 33 (0)1 39 17 20 20
Fax number: + 33 (0)1 39 58 12 98
Email:info.pharma@aptar.comwww.aptar.com/pharma
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
